Use of white ganoderma lucidum polysaccharide

Abstract

The application belongs to the technical field of comprehensive utilization of edible and medicinal fungi, and particularly relates to a use of white-fleshed ganoderma polysaccharide. The application discloses application of the white-fleshed ganoderma polysaccharide in preparation of food or medicine for preventing or treating chronic fatigue syndrome. The application also provides a use of the white-fleshed ganoderma polysaccharide in preventing or treating chronic fatigue syndrome, mainly improving weight loss, loss of appetite, memory loss and depression caused by chronic fatigue syndrome. In particular, the application also provides a preparation method of the white-fleshed ganoderma polysaccharide with the above use. The white-fleshed ganoderma polysaccharide is found to have a good effect of improving weight loss, loss of appetite, memory loss and depression caused by chronic fatigue syndrome, and can effectively relieve chronic fatigue syndrome, thereby providing a new way for application of white-fleshed ganoderma fruiting bodies.

Description

Technical Field

[0001] This invention belongs to the field of comprehensive utilization technology of edible and medicinal fungi, specifically the use of polysaccharides from Ganoderma lucidum. Background Technology

[0002] Edible fungi are a class of organisms rich in various health-promoting and medicinal components. Studies have shown that edible fungi contain active substances such as polysaccharides, polypeptides, nucleosides, and terpenes, exhibiting antibacterial, antitumor, anti-inflammatory, lipid-lowering, anti-atherosclerotic, antifungal, and antiviral effects. In recent years, scholars both domestically and internationally have conducted in-depth research on the active substances in edible fungi, particularly on bioactive polysaccharides and bioactive protein polypeptides. Edible fungi have become a part of people's lives as a health food.

[0003] Chronic fatigue syndrome (CFS) is a complex chronic disease involving multiple systems. Its main clinical manifestations are persistent or recurrent fatigue lasting more than six months, unrelieved by rest, accompanied or absent physical symptoms such as headache and muscle pain, as well as psychological symptoms such as depression, anxiety, and insomnia. Recent data shows that the global prevalence of CFS is approximately 1%, primarily affecting adults and children, with a higher prevalence in women than men. In my country, the incidence of CFS is increasing annually, mainly concentrated in the 30-40 age group. The US Centers for Disease Control and Prevention predicts that CFS will become one of the major factors affecting human health in the 21st century. Although the etiology of CFS is not yet fully understood, most scholars believe that viral infections, psychosocial stress, family genetic factors, neuroendocrine system disorders, weakened immune function, and irregular lifestyles are related to its development. Statistics show that more than half of CFS patients are unable to work, and only 19% are able to maintain a semblance of employment. Currently, Western medicine primarily treats CFS through psychological intervention and cognitive therapy, employing antiviral, antidepressant, immunosuppressive, analgesic, and sleep-improving methods to alleviate symptoms. However, these approaches suffer from numerous adverse reactions, poor patient compliance, and unsatisfactory efficacy. Therefore, finding medications to treat chronic fatigue syndrome is crucial.

[0004] Polysaccharides are a class of biomolecules formed by multiple sugar molecules linked by glycosidic bonds. They are important carbohydrates in living organisms, possessing a complex structure of multiple monosaccharide molecules. These sugar molecules are linked by various glycosidic bonds, forming linear or branched structures. In living organisms, polysaccharides play important physiological functions, including providing energy, maintaining cell structure, and participating in cell communication. Reports on the extraction and application of polysaccharides are mostly focused on those from edible fungi, such as Ganoderma lucidum polysaccharides and Trametes versicolor polysaccharides, which possess a range of health benefits, including regulating the immune system, antioxidation, and antitumor effects. However, research on polysaccharides from edible (and medicinal) fungi primarily focuses on their antibacterial, antitumor, anti-inflammatory, and antioxidant properties, with a lack of research on their anti-fatigue effects.

[0005] White-fleshed Ganoderma lucidum Ganoderma leucocontextum Also known as white Ganoderma, Tibetan white Ganoderma, or Tibetan Ganoderma, it belongs to the Basidiomycetes phylum. Basidiomycota Agaricomycetes Agaricomycetes Lingzhi Eye Polyporales Ganodermacetes Ganodermataceae Due to the unique natural environment of Tibet, white-fleshed Ganoderma lucidum has a higher content of active ingredients such as polysaccharides and triterpenes, and is regarded as a high-end Ganoderma lucidum variety. Both the fruiting body and mycelial fermentation products of white-fleshed Ganoderma lucidum have excellent health benefits. The Tibetan medical classic "Jingzhu Bencao" records Tibetan Ganoderma lucidum as a tonic and strengthening medicine, with effects such as treating altitude sickness, blood deficiency, neurasthenia, palpitations, dizziness, and calming the mind. Existing research (Xiong Chuan, Chen Cheng, Chen Zuqin, et al. Study on the effect of Ganoderma lucidum water extract on promoting PC-12 cell differentiation [J]. Natural Product Research and Development, 2016, 28(07):1135-1138+1143. Xiong Chuan, Chen Cheng, Huang Wenli, et al. Protective effect of Ganoderma lucidum water extract on H2O2-induced PC12 cell apoptosis [J]. Journal of Food Safety and Quality Testing, 2016, 7(02):662-668. Wang Yu, Qin Xu, He Jiujun, et al. Protective effect of Ganoderma lucidum water extract on neuronal damage after cerebral ischemia [J]. Journal of Northwest University for Nationalities (Natural Science Edition), 2021, 42 (03): 31-36. Wang Yu, Qin Xu, He Jiujun. Protective effect of Ganoderma lucidum water extract on hippocampal neurons in rats with cerebral ischemia [J]. China Animal Husbandry and Veterinary Medicine, 2021, 48 (10): 3864-3871. Wang Yu, Qin Xu, He Jiujun, et al. Effects of Ganoderma lucidum water extract on improving cognitive function in aging rats [J]. Acta Anatomica Sinica, 2022, 53(06):711-718.) indicates that Ganoderma lucidum water extract has the effects of inducing cell differentiation, inhibiting cell apoptosis, anti-oxidation, and neuroprotection.

[0006] The academic paper "Study on the protective effect of Ganoderma lucidum polysaccharide on exercise-induced fatigue in mice based on Keap1 / Nrf2 / HO-1 signaling pathway and oxidative stress effect" (Tian Xing, Lu Congcong. Study on the protective effect of Ganoderma lucidum polysaccharide on exercise-induced fatigue in mice based on Keap1 / Nrf2 / HO-1 signaling pathway and oxidative stress effect [J]. China Food Additives, 2023, 34(01):127-136.) reported the protective effect of Ganoderma lucidum polysaccharide on exercise-induced fatigue in mice. However, this literature did not study the efficacy of Ganoderma lucidum polysaccharide on chronic fatigue syndrome. Summary of the Invention

[0007] The purpose of this invention is to address the lack of existing records regarding the effects of Ganoderma lucidum polysaccharides on chronic fatigue syndrome (CFS), and to provide a novel application for Ganoderma lucidum polysaccharides: their use in the preparation of drugs for the prevention or treatment of CFS. This invention extracts Ganoderma lucidum polysaccharides from the fruiting body of Ganoderma lucidum and, for the first time, discovers that these polysaccharides have a good therapeutic and relieving effect on CFS. Using Ganoderma lucidum polysaccharides in the preparation of drugs for the prevention or treatment of CFS can effectively achieve the therapeutic and relieving effects of CFS.

[0008] To achieve the above-mentioned objectives, the specific technical solution of the present invention is as follows: Application of white-fleshed Ganoderma lucidum polysaccharide in the preparation of drugs for the prevention or treatment of chronic fatigue syndrome.

[0009] Furthermore, the prevention or treatment of chronic fatigue syndrome includes persistent or recurrent fatigue lasting more than 6 months that cannot be relieved by rest, accompanied or not accompanied by physical symptoms such as headache and muscle pain, and at least one of psychological symptoms such as depression, anxiety, and insomnia.

[0010] Furthermore, in the application of the above-mentioned white-fleshed Ganoderma lucidum polysaccharide, the drug dosage form includes at least one of capsules, tablets, oral liquids or injections.

[0011] In the application of the aforementioned white-fleshed Ganoderma lucidum polysaccharide, the prevention or treatment of chronic fatigue syndrome mainly improves weight loss and loss of appetite, alleviates memory decline and depression caused by chronic fatigue syndrome.

[0012] Preferably, the preparation method of the white-fleshed Ganoderma lucidum polysaccharide is as follows: the white-fleshed Ganoderma lucidum fruiting body is dried and pulverized to obtain a dried powder of the white-fleshed Ganoderma lucidum fruiting body, anhydrous ethanol is added, the powder is soaked overnight, and then centrifuged and dried. Then, the powder is extracted with water and ethanol, protein is removed by Savage reagent, concentrated, dialyzed, and dried to obtain crude white-fleshed Ganoderma lucidum polysaccharide.

[0013] Furthermore, in the aforementioned new uses of Ganoderma lucidum polysaccharide, during the preparation of the polysaccharide, the ratio of Ganoderma lucidum fruiting body to anhydrous ethanol for soaking is 1:10 (M / V); the water extraction and alcohol precipitation are performed by extracting three times (6h / time) with 95℃ distilled water (the amount of distilled water added is based on a ratio of 1:15 of the mass g of Ganoderma lucidum fruiting body to the volume ml of distilled water), combining the extracts, concentrating them to 100mL by low-temperature rotary evaporation, adding 500mL of anhydrous ethanol, allowing it to stand overnight at 4℃, and collecting the precipitate; the Savage reagent is chloroform: n-butanol = 4:1, V / V; the dialysis is performed in a dialysis bag with a molecular weight cutoff of 7500kD.

[0014] Among the novel uses of Ganoderma lucidum polysaccharides, the preparation method of Ganoderma lucidum polysaccharides further includes a purification step; the purification process is as follows: the crude polysaccharides of Ganoderma lucidum are dissolved in sterile water, passed through a DEAE cellulose-52 ion exchange column, the absorbance is measured at 490 nm, the eluent of each main peak is collected and freeze-dried to obtain polysaccharides of different grades; the absorbance is measured at 490 nm through a Sephadex G-100 gel chromatography column, the eluent of each main peak is collected, the eluents are combined and concentrated by low-temperature rotary evaporation, and then freeze-dried to obtain Ganoderma lucidum polysaccharides.

[0015] In the further purification step of the preparation method of Ganoderma lucidum polysaccharide, the DEAE cellulose-52 ion exchange column is 4.5 × 80 cm; the mobile elution phase of the DEAE cellulose-52 ion exchange column is 0 mol / L, 0.1 mol / L, 0.2 mol / L, 0.3 mol / L, 0.5 mol / L, and 1 mol / L NaCl; the Sephadex G-100 gel chromatography column is 2 × 100 cm; and the mobile elution phase of the Sephadex G-100 gel chromatography column is ddH2O.

[0016] Compared with existing technologies, the beneficial effects of this invention are: This invention extracts Ganoderma lucidum polysaccharides from the fruiting bodies of Ganoderma lucidum and discovers for the first time that these polysaccharides have a good therapeutic effect on chronic fatigue syndrome. These polysaccharides can effectively improve weight loss and loss of appetite caused by chronic fatigue syndrome, alleviate memory decline, and alleviate depression. Therefore, this invention provides a use of Ganoderma lucidum polysaccharides in the preparation of drugs for the prevention or treatment of chronic fatigue syndrome, offering a new approach to the application of Ganoderma lucidum fruiting bodies. Attached Figure Description

[0017] Figure 1 The image shown is a scanning electron microscope (SEM) image of the purified Ganoderma lucidum polysaccharide. Figure 2The figure shows the weight changes of rats during the modeling stage; Figure 3 The figure shows the changes in food intake of rats during the modeling stage; Figure 4 The figure shows the changes in water intake of rats during the modeling stage; Figure 5 The figure shows the weight changes of rats during the treatment phase; Figure 6 The figure shows the average daily food and water intake of rats during the treatment phase. Detailed Implementation

[0018] Prior to this invention, research on Ganoderma lucidum polysaccharides in this industry mainly focused on extraction and anti-tumor effects, while research on the application of Ganoderma lucidum polysaccharides was limited, and there were no reports on the effects of Ganoderma lucidum polysaccharides on chronic fatigue syndrome.

[0019] This invention creatively discovers the use of Ganoderma lucidum polysaccharide in the preparation of drugs for the prevention or treatment of chronic fatigue syndrome. In this novel use of Ganoderma lucidum polysaccharide, the drug dosage form includes at least one of capsules, tablets, oral liquids, or injections.

[0020] The prevention or treatment of chronic fatigue syndrome described in this invention includes persistent or recurrent fatigue lasting more than 6 months, which cannot be relieved by rest, accompanied or not accompanied by physical symptoms such as headache and muscle pain, as well as psychological symptoms such as depression, anxiety, and insomnia. This invention also creatively discovers that Ganoderma lucidum polysaccharides can improve weight loss and loss of appetite, alleviate memory decline, and alleviate depressive symptoms caused by chronic fatigue syndrome.

[0021] Preferably, the present invention also provides a method for preparing Ganoderma lucidum polysaccharides for the above-mentioned uses, but this does not mean that only Ganoderma lucidum polysaccharides prepared by the following method have this use. Ganoderma lucidum polysaccharides prepared by other methods also have the same use in the preparation of drugs for the prevention or treatment of chronic fatigue syndrome.

[0022] This invention provides a method for preparing polysaccharides from white-fleshed Ganoderma lucidum, comprising the following steps: a. Harvest white-fleshed Ganoderma lucidum and treat it in an oven at 37-45℃ for 12-16 hours to make the moisture content of the dried white-fleshed Ganoderma lucidum ≤13%. Then, pulverize it using a Chinese medicine pulverizer and sieve it through an 80-mesh sieve to obtain dried white-fleshed Ganoderma lucidum fruiting body powder. b. Weigh the dried fruiting body powder of Ganoderma lucidum (white flesh) and soak it in 95% ethanol at a material-to-liquid ratio of 1:10 (M / V) for 24 h. Repeat this process twice. After drying at room temperature, set aside for later use. After pretreatment, add distilled water at a material-to-liquid ratio of 1:15 (M / V) and extract three times at 95℃ (6 h / time). Centrifuge (3000 r / min, 12 min), combine the extracts, concentrate to 100 mL by low-temperature rotary evaporation, add 500 mL of anhydrous ethanol, let stand overnight at 4℃, centrifuge (3000 r / min, 15 min), collect the precipitate and redissolve it with distilled water. Remove the protein using Savage reagent (chloroform: n-butanol = 4:1, V / V). Then dialyze with running water for 48 h using a dialysis bag (molecular weight cutoff 7500 kD) to remove monosaccharides and small molecule inorganic salts and other impurities. Freeze-dry to obtain crude polysaccharide.

[0023] c. Using a DEAE cellulose-52 ion exchange column (4.5×80cm), with 0 mol / L, 0.1 mol / L, 0.2 mol / L, 0.3 mol / L, 0.5 mol / L, and 1 mol / L NaCl as the mobile eluent, DEAE cellulose-52 elution chromatograms were plotted. The test tubes corresponding to each main peak were collected, and the eluents were combined and concentrated by low-temperature rotary evaporation. Further desalting was performed by dialyzing, and the resulting fractions were freeze-dried to obtain different grades of Ganoderma lucidum polysaccharides.

[0024] d. Using a Sephadex G-100 gel chromatography column (2×100cm), construct the Sephadex G-100 elution chromatogram, collect the test tubes corresponding to each main peak, combine the eluents, concentrate by low-temperature rotary evaporation, and freeze-dry to obtain white-fleshed Ganoderma lucidum polysaccharide (refined polysaccharide).

[0025] All features disclosed in this specification, or all steps in all disclosed methods or processes, may be combined in any way, except for mutually exclusive features and / or steps.

[0026] Any feature disclosed in this specification (including the claims and abstract) may be replaced by other equivalent or similar features, unless specifically stated otherwise. That is, unless specifically stated otherwise, each feature is merely one example of a series of equivalent or similar features.

[0027] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0028] Example 1: Preparation of polysaccharides from white-fleshed Ganoderma lucidum Weigh 1 kg of dried white-fleshed Ganoderma lucidum fruiting body, pulverize it using a traditional Chinese medicine pulverizer, and sieve it through an 80-mesh sieve to obtain powder of dried white-fleshed Ganoderma lucidum fruiting body.

[0029] Weigh 200g of dried Ganoderma lucidum fruiting body powder, add 95% ethanol at a material-to-liquid ratio of 1:10 (m / v) and soak for 24 h. Repeat this process twice. After drying at room temperature, set aside for later use. After pretreatment, add distilled water at a material-to-liquid ratio of 1:15 (M / V) and extract three times at 95℃ (6 h / time). Centrifuge (3000 r / min, 12 min), combine the extracts, concentrate to 100 mL by low-temperature rotary evaporation, add 500 mL of anhydrous ethanol, let stand overnight at 4℃, centrifuge (3000 r / min, 15 min), collect the precipitate and redissolve with distilled water. Remove protein using Savage reagent (chloroform: n-butanol = 4:1, V / V). Dialyze with running water for 48 h using a dialysis bag (molecular weight cutoff 7500 kD) to remove monosaccharides and small molecule inorganic salts and other impurities. Freeze-dry to obtain crude polysaccharide.

[0030] A 10% crude polysaccharide solution of Ganoderma lucidum was prepared and passed through a DEAE cellulose-52 ion exchange column (4.5 × 80 cm). 10 mL of the crude polysaccharide solution was loaded onto the column. The mobile eluent was prepared using 0 mol / L, 0.1 mol / L, 0.2 mol / L, 0.3 mol / L, 0.5 mol / L, and 1 mol / L NaCl as the mobile eluent at a flow rate of 0.5 mL / min. 5 mL of eluent was collected from each tube using an automatic collector. The polysaccharides were detected using the phenol-sulfuric acid method at a wavelength of 490 nm. A DEAE cellulose-52 elution chromatogram was plotted with the number of tubes on the x-axis and the absorbance on the y-axis. The tubes corresponding to each main peak were collected, and the eluents were combined and concentrated by low-temperature rotary evaporation. Further desalting by dialyzing and freeze-drying yielded different fractions of Ganoderma lucidum polysaccharides.

[0031] 100 mg of polysaccharide obtained by DEAE cellulose-52 column chromatography was dissolved in 5 mL of ddH2O. A Sephadex G-100 gel chromatography column (2×100 cm) was used with ddH2O as the mobile phase and a flow rate of 2 mL / min. The eluent was collected using an automatic collector, and 5 mL of each tube was collected. The polysaccharide was detected by the phenol-sulfuric acid method with a wavelength of 490 nm. The x-axis represents the number of test tubes and the y-axis represents the absorbance value. A Sephadex G-100 elution chromatogram was plotted. The test tubes corresponding to each main peak were collected, and the eluent was combined and concentrated by low-temperature rotary evaporation. After freeze-drying, the polysaccharide of Ganoderma lucidum (refined polysaccharide) was obtained.

[0032] The crude polysaccharide obtained was 5.83g, with a yield of 2.92% (5.83g of crude polysaccharide can be obtained after extracting 200g of Ganoderma lucidum powder), and the polysaccharide obtained was 0.33g, with a yield of 5.71%.

[0033] Repeat the above preparation process to prepare sufficient amounts of white-fleshed Ganoderma lucidum polysaccharide GLP.

[0034] Example 2: Effects of Ganoderma lucidum polysaccharide on diet, water intake, and body weight in rats with chronic fatigue syndrome After a week of acclimatization, 24 female rats were randomly divided into a quiet group (n=8) and a fatigue group (n=16). The quiet group was housed in a 35cm×5cm×15cm enclosure in a separate room, while the fatigue group (n=16) was housed in a 50cm×35cm×20cm enclosure. Both groups received daily exercise interventions (treadmill training: 5° incline, 30 min) and psychological interventions (restraint, crowding, sunlight, and noise). The specific intervention schedule was as follows: noise intervention (8:00 PM - 8:00 AM), treadmill training (11:00 AM - 12:00 PM), and restraint intervention (2:00 PM - 4:00 PM). The modeling phase lasted 21 days, and both groups had no restrictions on food or water intake. After 7 days of treatment, the fatigue group was randomly divided into a CFS treatment group (n=8) and a GLP group (n=8). All interventions remained the same, except for the water intake: the GLP group was administered 200 mg / L of Ganoderma lucidum polysaccharide by gavage, while the quiet group and the CFS treatment group were administered the same volume of distilled water by gavage.

[0035] Changes in body weight, diet, and water intake of rats were recorded during the acclimatization period (7 days), modeling period (21 days), and treatment period (7 days). Body weight was measured every two days, while other changes were measured daily.

[0036] Weight, diet, and water intake during the modeling stage, such as Figure 3 Figure 4 As shown, on the tenth day of modeling, the food and water intake of rats in the fatigue group began to decrease, showing a difference compared with the resting group. P <0.05). In the later stages of modeling, the food and water intake of rats in the fatigue group began to increase slowly, possibly related to the rats' adaptation. Starting from day 3 (day 10) of modeling, the body weight of the fatigue group was significantly different from that of the resting group. P <0.05), showing a highly significant difference in the middle and late stages ( P <0.05) indicates that the intervention has affected the rat's body weight.

[0037] Weight, diet, and fluid intake during treatment, such as Figure 5 Figure 6 As shown, the body weight of the quiet group rats showed a slow upward trend, while the body weight of the CFS group rats remained significantly lower than that of the quiet group. P <0.05), the GLP group rats were on par with the CFS group at the beginning of treatment, but began to increase in the middle and late stages of treatment. The average daily food and water intake of the CFS group was lower than that of Anjingjie, and there was a significant difference in food intake. P <0.05), there was no significant difference in average daily water intake between the two groups. P <0.05); the average daily food intake in the GLP treatment group was significantly different from that in the CFS group (P <0.05); there was no significant difference in water intake between the quiet group and the CFS group, or between the GLP group and the CFS group. P >0.05).

[0038] The results of GLP treatment showed that, compared with the CFS group, the weight, daily food intake and water intake of rats in the GLP group were significantly increased, indicating that GLP can improve the weight loss and reduced food and water intake caused by chronic fatigue.

[0039] Example 3: Water Maze Experiment The experiment used the Morris water maze experimental setup provided by Beijing Zhongshi Dichuang Technology Co., Ltd. The maze parameters were: water depth 1.6 meters, platform diameter 12 centimeters, and height 35 centimeters. The experiment was conducted in a quiet environment. A four-day learning phase began on the 17th day of model building, followed by an exploration phase on the 5th day.

[0040] The learning experiment involved fixing a safety platform in the third quadrant of a water maze and filling it with water to submerge the platform by approximately 1.5 cm. Two groups of rats (a resting group and a fatigued group) were then placed into the water sequentially from the first, second, third, and fourth quadrants, facing the maze wall. The time (latency period), distance traveled, and speed of each rat from entry into the water to successfully finding the platform were measured within 60 seconds to evaluate the animals' spatial learning abilities. Each rat was trained once per day in each of the four quadrants. If a rat failed to reach the platform within 60 seconds, it was guided to do so and remain on the platform for 10 seconds to help it memorize its location.

[0041] The spatial exploration experiment was conducted on the fifth day after the learning phase ended, at which point the safety platform was removed. Rats were placed in the water facing the pool wall from the first quadrant. The number of times the rats crossed the original platform position, the time spent in that quadrant, and the percentage of the total exploration time during that period were observed. Each rat only participated in the first quadrant.

[0042] The results showed that there was no significant difference in the average speed at which rats in the quiet group, CFS group, and GLP group searched for the platform. P >0.05); the distance and time spent by rats in the CFS group within the quadrant where the platform was located were significantly different compared to the quiet group. P <0.05, P <0.01), the GLP group had a significantly longer activity distance than the CFS group ( P <0.05), and the time spent in the surrounding area was also significantly longer than that in the CFS group ( P <0.01); Regarding the number of times the patient crossed the platform, the CFS group had more cases than the quiet group, but the difference was not statistically significant. P >0.05), the GLP group showed a significant difference compared to the CFS group ( P <0.05).

[0043]

[0044] The results of this experiment show that after GLP intervention, the rats in this group had significant differences from the chronic fatigue group (CFS) in terms of activity time around the platform, activity distance around the platform, and number of times they crossed the platform, indicating that GLP can effectively alleviate the symptoms of memory decline caused by chronic fatigue.

[0045] Example 4: Mine Field Experiment The testing conditions for the mine-field experimental setup included sound insulation and light protection. The test chamber measured 100×100×50 cm and had no top baffle. The bottom of the chamber was black with 25 equally sized squares formed by four horizontal and four vertical white lines. A camera was mounted in the center of the top of the chamber to record the experimental process. Experimental method: Each rat was tested once, placed in the square in the center of the bottom of the mine-field test chamber. The distance the rat traveled in the chamber, its average speed, the number of times it stood up, and the number of times it modified its position were measured. The test lasted for 300 seconds. After each rat completed the test, the chamber was wiped clean and disinfected to prevent odor interference.

[0046] The experimental results are shown in Table 2. The CFS rats had a shorter distance traveled in the mine, lower average speed, fewer standing times, and fewer modification times than the resting rats, and the differences were statistically significant. P <0.05, P <0.01), among which, there was a highly significant difference in the number of standing times ( P <0.01); The distance traveled, average speed, and number of standing times of rats in the GLP group were significantly different from those in the CFS group in the mine. P <0.05), with no significant difference compared to the quiet group ( P >0.05).

[0047] The results of this experiment show that after GLP treatment, the exploratory behavior and spontaneous activity of rats in the GLP treatment group increased significantly, and their activity speed increased. This indicates that after GLP intervention, the activity capacity and adaptability of the rats in the treatment group were enhanced, suggesting that GLP can effectively alleviate emotional problems caused by fatigue.

[0048]

[0049] The embodiments described above merely illustrate specific implementation methods of this application, and while the descriptions are detailed and specific, they should not be construed as limiting the scope of protection of this application. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the technical solution of this application, and these modifications and improvements all fall within the scope of protection of this application.

[0050] This background section is provided to generally present the context of the invention. The work of the currently named inventors, the work to the extent described in this background section, and aspects of this section that did not constitute prior art at the time of application are neither expressly nor impliedly acknowledged as prior art to the invention.

Claims

1. The application of white-fleshed Ganoderma lucidum polysaccharide in the preparation of drugs for the prevention or treatment of chronic fatigue syndrome, characterized in that: The preparation method of Ganoderma lucidum polysaccharide is as follows: the fruiting body of Ganoderma lucidum is dried and pulverized to obtain dried powder of Ganoderma lucidum fruiting body; then anhydrous ethanol is added, soaked overnight, and centrifuged and dried; then the protein is removed by water extraction and alcohol precipitation, Savage reagent, concentration, dialysis, and drying to obtain crude polysaccharide of Ganoderma lucidum; the preparation method of Ganoderma lucidum polysaccharide also includes a purification step; the purification process is as follows: the crude polysaccharide of Ganoderma lucidum is dissolved in sterile water, passed through a DEAE cellulose-52 ion exchange column, the absorbance value is measured at 490 nm, the eluent of each main peak is collected and freeze-dried to obtain polysaccharides of different fractions; the absorbance value is measured at 490 nm through a Sephadex G-100 gel chromatography column, the eluent of each main peak is collected, the eluents are combined and concentrated by low-temperature rotary evaporation, and then freeze-dried to obtain Ganoderma lucidum polysaccharide.

2. The application according to claim 1, characterized in that: The dosage form of the drug is capsules, tablets, oral liquid, or injection.

3. The application according to claim 1, characterized in that: The ratio of the mass (g) of dried Ganoderma lucidum fruiting body powder to the volume (ml) of anhydrous ethanol is 1:

10. The water extraction and alcohol precipitation are performed as follows: extract three times with distilled water at 95℃, 6 hours each time, combine the extracts, concentrate by low-temperature rotary evaporation, add anhydrous ethanol, let stand overnight at 4℃, and collect the precipitate.

4. The application according to claim 1, characterized in that: The Savage reagent is obtained by mixing chloroform and n-butanol in a volume ratio of 4:

1.

5. The application according to claim 1, characterized in that: In the purification step of the preparation method of Ganoderma lucidum polysaccharide, the DEAE cellulose-52 ion exchange column is 4.5×80cm; the mobile elution phase of the DEAE cellulose-52 ion exchange column is 0mol / L, 0.1mol / L, 0.2mol / L, 0.3mol / L, 0.5mol / L, and 1mol / L NaCl; the Sephadex G-100 gel chromatography column is 2×100cm; and the mobile elution phase of the Sephadex G-100 gel chromatography column is ddH2O.

Images